Literature DB >> 32247864

Comparison of GeneChip, nCounter, and Real-Time PCR-Based Gene Expressions Predicting Locoregional Tumor Control after Primary and Postoperative Radiochemotherapy in Head and Neck Squamous Cell Carcinoma.

Stefan Schmidt1, Annett Linge2, Marianne Grosser3, Fabian Lohaus4, Volker Gudziol5, Alexander Nowak6, Ingeborg Tinhofer7, Volker Budach7, Ali Sak8, Martin Stuschke8, Panagiotis Balermpas9, Claus Rödel9, Henning Schäfer10, Anca-Ligia Grosu10, Amir Abdollahi11, Jürgen Debus12, Ute Ganswindt13, Claus Belka14, Steffi Pigorsch15, Stephanie E Combs16, David Mönnich17, Daniel Zips18, Gustavo B Baretton19, Frank Buchholz20, Michael Baumann21, Mechthild Krause22, Steffen Löck4.   

Abstract

This article compares the expression and applicability of biomarkers, from single genes and gene signatures, identified in patients with locally advanced head and neck squamous cell carcinoma using the GeneChip Human Transcriptome Array 2.0, nCounter, and real-time PCR analyses. Two multicenter, retrospective cohorts of patients with head and neck squamous cell carcinoma from the German Cancer Consortium Radiation Oncology Group who received postoperative radiochemotherapy or primary radiochemotherapy were considered. Real-time PCR was performed for a limited number of 38 genes of the cohort who received postoperative radiochemotherapy only. Correlations between the methods were evaluated by the Spearman rank correlation coefficient. Patients were stratified based on the expression of putative cancer stem cell markers, hypoxia-associated gene signatures, and a previously developed seven-gene signature. Locoregional tumor control was compared between these patient subgroups using log-rank tests. Gene expressions obtained from nCounter analyses were moderately correlated to GeneChip analyses (median ρ = approximately 0.68). A higher correlation was obtained between nCounter analyses and real-time PCR (median ρ = 0.84). Significant associations with locoregional tumor control were observed for most of the considered biomarkers evaluated by GeneChip and nCounter analyses. In general, all applied biomarkers (single genes and gene signatures) classified approximately 70% to 85% of the patients similarly. Overall, gene signatures seem to be more robust and had a better transferability among different measurement methods.
Copyright © 2020 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32247864     DOI: 10.1016/j.jmoldx.2020.03.005

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  4 in total

1.  A Novel 2-Metagene Signature to Identify High-Risk HNSCC Patients amongst Those Who Are Clinically at Intermediate Risk and Are Treated with PORT.

Authors:  Shivaprasad Patil; Annett Linge; Hannah Hiepe; Marianne Grosser; Fabian Lohaus; Volker Gudziol; Max Kemper; Alexander Nowak; Dominik Haim; Inge Tinhofer; Volker Budach; Maja Guberina; Martin Stuschke; Panagiotis Balermpas; Jens von der Grün; Henning Schäfer; Anca-Ligia Grosu; Amir Abdollahi; Jürgen Debus; Ute Ganswindt; Claus Belka; Steffi Pigorsch; Stephanie E Combs; Simon Boeke; Daniel Zips; Korinna Jöhrens; Gustavo B Baretton; Michael Baumann; Mechthild Krause; Steffen Löck
Journal:  Cancers (Basel)       Date:  2022-06-20       Impact factor: 6.575

Review 2.  Tumor Hypoxia Regulates Immune Escape/Invasion: Influence on Angiogenesis and Potential Impact of Hypoxic Biomarkers on Cancer Therapies.

Authors:  Raefa Abou Khouzam; Klaudia Brodaczewska; Aleksandra Filipiak; Nagwa Ahmed Zeinelabdin; Stephanie Buart; Cezary Szczylik; Claudine Kieda; Salem Chouaib
Journal:  Front Immunol       Date:  2021-01-20       Impact factor: 7.561

3.  Small Extracellular Vesicles from Head and Neck Squamous Cell Carcinoma Cells Carry a Proteomic Signature for Tumor Hypoxia.

Authors:  Alicja Głuszko; Mirosław J Szczepański; Theresa L Whiteside; Torsten E Reichert; Jacek Siewiera; Nils Ludwig
Journal:  Cancers (Basel)       Date:  2021-08-19       Impact factor: 6.639

4.  Integrated radiogenomics analyses allow for subtype classification and improved outcome prognosis of patients with locally advanced HNSCC.

Authors:  Asier Rabasco Meneghetti; Alex Zwanenburg; Annett Linge; Fabian Lohaus; Marianne Grosser; Gustavo B Baretton; Goda Kalinauskaite; Ingeborg Tinhofer; Maja Guberina; Martin Stuschke; Panagiotis Balermpas; Jens von der Grün; Ute Ganswindt; Claus Belka; Jan C Peeken; Stephanie E Combs; Simon Böke; Daniel Zips; Esther G C Troost; Mechthild Krause; Michael Baumann; Steffen Löck
Journal:  Sci Rep       Date:  2022-10-06       Impact factor: 4.996

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.